search button

The prognostic significance of PD-L1 in bladder cancer

  • Authors:
    • Yide Huang
    • Shu-Dong Zhang
    • Cian McCrudden
    • Kwok-Wah Chan
    • Yao Lin
    • Hang-Fai Kwok

  • View Affiliations

  • Published online on: April 27, 2015     https://doi.org/10.3892/or.2015.3933
  • Pages: 3075-3084
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Immunotherapy is a promising strategy for the treatment of various types of cancer. An antibody that targets programmed death ligand-1 (PD-L1) pathway has been shown to be active towards various types of cancer, including melanoma and lung cancer. MPDL3280A, an anti‑PD-L1 antibody, has shown clear clinical activity in PD-L1-overexpressing bladder cancer with an objective response rate of 40-50%, resulting in a breakthrough therapy designation granted by FDA. These events pronounce the importance of targeting the PD-L1 pathway in the treatment of bladder cancer. In the present study, we investigated the prognostic significance of the expression of three genes in the PD-L1 pathway, including PD-L1, B7.1 and PD-1, in three independent bladder cancer datasets in the Gene Expression Omnibus database. PD-L1, B7.1 and PD-1 were significantly associated with clinicopathological parameters indicative of a more aggressive phenotype of bladder cancer, such as a more advanced stage and a higher tumor grade. In addition, a high level expression of PD-L1 was associated with reduced patient survival. Of note, the combination of PD-L1 and B7.1 expression, but not other combinations of the three genes, were also able to predict patient survival. Our findings support the development of anti-PD-L1, which blocks PD-L1-PD-1 and B7.1-PD-L1 interactions, in treatment of bladder cancer. The observations were consistent in the three independent bladder cancer datasets consisting of a total of 695 human bladder specimens. The datasets were then assessed and it was found that the expression levels of the chemokine CC-motif ligand (CCL), CCL3, CCL8 and CCL18, were correlated with the PD-L1 expression level, while ADAMTS13 was differentially expressed in patients with a different survival status (alive or deceased). Additional investigations are required to elucidate the role of these genes in the PD-L1-mediated immune system suppression and bladder cancer progression. In conclusion, findings of this study suggested that PD-L1 is an important prognostic marker and a therapeutic target for bladder cancer.
View Figures
View References

Related Articles

Journal Cover

June-2015
Volume 33 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.8
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.5
  • CiteScore Rank: Q1: #74/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.719
  • SCImago Journal Rank (SJR): 0.864
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Huang Y, Zhang S, McCrudden C, Chan K, Lin Y and Kwok H: The prognostic significance of PD-L1 in bladder cancer. Oncol Rep 33: 3075-3084, 2015.
APA
Huang, Y., Zhang, S., McCrudden, C., Chan, K., Lin, Y., & Kwok, H. (2015). The prognostic significance of PD-L1 in bladder cancer. Oncology Reports, 33, 3075-3084. https://doi.org/10.3892/or.2015.3933
MLA
Huang, Y., Zhang, S., McCrudden, C., Chan, K., Lin, Y., Kwok, H."The prognostic significance of PD-L1 in bladder cancer". Oncology Reports 33.6 (2015): 3075-3084.
Chicago
Huang, Y., Zhang, S., McCrudden, C., Chan, K., Lin, Y., Kwok, H."The prognostic significance of PD-L1 in bladder cancer". Oncology Reports 33, no. 6 (2015): 3075-3084. https://doi.org/10.3892/or.2015.3933